| Patent application number | Description | Published |
|---|
| 20080300166 | Treatment of Melanoma with Alpha Thymosin Peptides - A method of treating melanoma or a metastasis thereof in a human patient by administering a melanoma-treating effective amount of an alpha thymosin peptide to a human melanoma patient, wherein the human melanoma patient does not have a substantially elevated LDH blood level. | 12-04-2008 |
| 20090074815 | Immunomodulator Compounds as Vaccine Enhancers - A vaccination method utilizes a pharmaceutical combination for enhancing vaccine effectiveness. The method utilizes an immune response-triggering vaccine capable of stimulating production in an immunodefficicent animal of antibodies to a disease-causing agent foreign to the animal. As an adjuvant, a vaccine effectiveness-enhancing amount of an immunomodulator compound is administered, which enhances production and affinity of the antibodies in the animal, in response to the vaccine. | 03-19-2009 |
| 20090088392 | TREATMENT OF MELANOMA - An immunomodulatory compound is administered to treat, prevent, inhibit, or reduce melanoma in a subject. | 04-02-2009 |
| 20090143313 | Treatment or Prevention of Hemorrhagic Viral Infections with Immunomodulator Compounds - An immunomodulatory compound is administered to a patient having, or at risk of a hemorrhagic viral infection. | 06-04-2009 |
| 20100016211 | Treatment of Melanoma With Alpha Thymosin Peptides - A method of treating melanoma or a metastasis thereof in a human patient by administering a melanoma-treating effective amount of an alpha thymosin peptide to a human melanoma patient, wherein the human melanoma patient does not have a substantially elevated LDH blood level. | 01-21-2010 |
| 20100197595 | TREATMENT OF MELANOMA WITH ALPHA THYMOSIN PEPTIDES - A method of treating melanoma or a metastasis thereof in a human patient by administering a melanoma-treating effective amount of an alpha thymosin peptide to a human melanoma patient, wherein the human melanoma patient does not have a substantially elevated LDH blood level. | 08-05-2010 |
| 20100221274 | METHOD OF ADMINISTERING A THYMOSIN ALPHA 1 PEPTIDE - A Thymosin alpha 1 (TA1) peptide is administered to a patient in need of immune stimulation so as to substantially continuously maintain an immune stimulating-effective amount of the TA1 peptide in the patient. The administration method may be by continuous infusion. | 09-02-2010 |
| 20100267637 | TREATMENT OF MELANOMA WITH ALPHA THYMOSIN PEPTIDES IN COMBINATION WITH A KINASE INHIBITOR - Melanoma or a metastasis thereof is treated in a human patient in a combination therapy which includes administering a melanoma-treating combination to a human melanoma patient during a treatment regimen, the combination including an alpha thymosin peptide and a kinase inhibitor. | 10-21-2010 |
| 20100285060 | ALPHA THYMOSIN PEPTIDES AS VACCINE ENHANCERS - The present invention provides methods of vaccination as well as pharmaceutical combinations and kits for enhancing vaccine effectiveness, including for immunodeficient or immunecompromised patients, including non-responders and low-responders to vaccination. As disclosed herein, the invention relates to administering a vaccine and a regimen of thymosin alpha peptide so as to provide higher antibody titers, speed the development of such antibody titers, and/or to provide for a longer duration of such antibody titers, thereby providing a greater protective effect. In another aspect, the invention allows for reducing a vaccine dose, such as an influenza vaccine dose, by administration of a thymosin peptide regimen. | 11-11-2010 |
| 20100317583 | TREATMENT OF MELANOMA WITH ALPHA THYMOSIN PEPTIDES IN COMBINATION WITH AN ANTINEOPLASTIC HEAT SHOCK APOPTOSIS ACTIVATOR (HSAA) - Melanoma or a metastasis thereof is treated in a human patient in a combination therapy which includes administering a melanoma-treating combination to a human melanoma patient during a treatment regimen, the combination including an alpha thymosin peptide and an antineoplastic heat shock apoptosis activator (HSAA) such as STA-4783 (and optionally an antineoplastic cytotoxic chemotherapeutic agent such as paclitaxel), and/or optionally one or more additional anti-melanoma agents. | 12-16-2010 |
| 20100330093 | TREATMENT OF MELANOMA WITH ALPHA THYMOSIN PEPTIDES IN COMBINATION WITH ANTIBODIES AGAINST CYTOTOXIC T LYMPHOCYTE-ASSOCIATED ANTIGEN 4 (CTLA4) - Melanoma or a metastasis thereof is treated in a human patient in a combination therapy which includes administering a melanoma-treating combination to a human melanoma patient during a treatment regimen, the combination including an alpha thymosin peptide and antibodies against cytotoxic T lymphocyte-associated antigen 4 (CTLA4). | 12-30-2010 |
